Feasibility Study of Single-Photon Emission Computed Tomography with Iodine-123 Labeled Metaiodobenzylguanidine for Preclinical Evaluation of Labetalol as a β-Adrenergic Receptor Blocker
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c01240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Yiseul Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul 01812, Korea. Hauptthemen laut MEDLINE: 3-Iodobenzylguanidine, Adrenergic beta-Antagonists, Iodine Radioisotopes, Labetalol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Among clinically used radiopharmaceuticals, iodine-123 labeled metaiodobenzylguanidine ([123I]mIBG) serves for diagnosing neuroendocrine tumors and obtaining images of myocardial sympathetic innervation. mIBG, a structural analogue of norepinephrine (NE), a neurotransmitter acting in peripheral and central nerves, follows a pathway similar to NE, transmitting signals through the NE transporter (NET) located at synaptic terminals. It moves through the body without decomposing, enabling noninvasive image evaluation. In this study, we aimed to quantify [123I]mIBG uptake in the adrenal glands using small animal single-photon emission computed tomography/computed tomography (SPECT/CT) images post [123I]mIBG administration. We investigated the possibility of assessing the effectiveness of β-adrenergic receptor blockers by quantifying SPECT/CT images and biodistribution results to determine the degree of [123I]mIBG uptake in the adrenal glands treated with labetalol, a known β-adrenergic receptor blocker. Upon intravenous administration of [123I]mIBG to mice, SPECT/CT images were acquired over time to confirm the in vivo distribution pattern, revealing a clear uptake in the adrenal glands. Labetalol inhibited the uptake of [123I]mIBG in cell lines expressing NET. A decrease in [123I]mIBG uptake in the adrenal glands was observed in the labetalol-treated group compared with the normal group through SPECT/CT imaging and biodistribution studies. These results demonstrate that SPECT/CT imaging with [123I]mIBG could be applicable for evaluating the preclinical efficacy of new antihypertensive drug candidates such as labetalol, a β-adrenergic receptor blocker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul 01812, Korea.
- Division of Applied RI, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul 01812, Korea.
ORCID-Profile: Yiseul Choi
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Choi, Y., Lee, E. S., Woo, S. K., Lee, K. C., Chung, H. K., & Kang, J. H. (2024). Feasibility Study of Single-Photon Emission Computed Tomography with Iodine-123 Labeled Metaiodobenzylguanidine for Preclinical Evaluation of Labetalol as a β-Adrenergic Receptor Blocker. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c01240
Vancouver
Choi Y, Lee ES, Woo SK, Lee KC, Chung HK, Kang JH. Feasibility Study of Single-Photon Emission Computed Tomography with Iodine-123 Labeled Metaiodobenzylguanidine for Preclinical Evaluation of Labetalol as a β-Adrenergic Receptor Blocker. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c01240
BibTeX
@article{Choi2024,
author = {Choi, Yiseul and Lee, Eun Sang and Woo, Sang-Keun and Lee, Kyo Chul and Chung, Hye Kyung and Kang, Joo Hyun},
title = {Feasibility Study of Single-Photon Emission Computed Tomography with Iodine-123 Labeled Metaiodobenzylguanidine for Preclinical Evaluation of Labetalol as a β-Adrenergic Receptor Blocker},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c01240}
}
EUVIMED